The clinical studies have demonstrated the synergistic effects of GIP and GLP-1 agonism on glucose metabolism and body weight in these unimolecular dual agonists (63, 76), marking a significant achievement in the pharmaceutical development of incretins, which will be further discussed in the next section
Randomization was conducted using an interactive web response system, assigning participants in a 6:1 ratio to one of several treatment arms: once-weekly subcutaneous Cagrilintide administered in doses of 0.3, 0.6, 1.2, 2.4, or 4.5 mg, once-daily liraglutide 3.0 mg, or a volume-matched placebo
Zepbound is available in single-dose pre-filled disposable pens and vials administered under the skin of the stomach, upper arm, or thigh on the same day every week, at any time that is most convenient for you
Descarca la ltima versin de nuestra app y actvala para no perderte nuestro mejor contenido .